PGNY Quote, Financials, Valuation and Earnings

The Cigna Group has a net margin of 4.65% compared to Progyny's net margin of 2.02%. Progyny's return on equity of 11.16% beat The Cigna Group's return on equity of 12.17%.

Progyny has a consensus price target of $26.25, signalling upside risk potential of 17.71%. On the other hand The Cigna Group has an analysts' consensus of $375.13 which suggests that it could grow by 16.89%. Given that Progyny has higher upside potential than The Cigna Group, analysts believe Progyny is more attractive than The Cigna Group.

Progyny has a beta of 1.372, which suggesting that the stock is 37.195% more volatile than S&P 500. In comparison The Cigna Group has a beta of 0.472, suggesting its less volatile than the S&P 500 by 52.821%.

Progyny has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. The Cigna Group offers a yield of 1.78% to investors and pays a quarterly dividend of $1.51 per share. Progyny pays -- of its earnings as a dividend. The Cigna Group pays out 45.63% of its earnings as a dividend. The Cigna Group's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Progyny quarterly revenues are $324M, which are smaller than The Cigna Group quarterly revenues of $65.5B. Progyny's net income of $15.1M is lower than The Cigna Group's net income of $1.3B. Notably, Progyny's price-to-earnings ratio is 39.12x while The Cigna Group's PE ratio is 17.77x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Progyny is 1.73x versus 0.35x for The Cigna Group. Usually stocks with elevated PS ratios are considered overvalued.

Clover Health Investments has a net margin of 4.65% compared to Progyny's net margin of -0.28%. Progyny's return on equity of 11.16% beat Clover Health Investments's return on equity of -7.67%.

Progyny has a consensus price target of $26.25, signalling upside risk potential of 17.71%. On the other hand Clover Health Investments has an analysts' consensus of $4.69 which suggests that it could grow by 32.04%. Given that Clover Health Investments has higher upside potential than Progyny, analysts believe Clover Health Investments is more attractive than Progyny.

Progyny has a beta of 1.372, which suggesting that the stock is 37.195% more volatile than S&P 500. In comparison Clover Health Investments has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Progyny has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Clover Health Investments offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Progyny pays -- of its earnings as a dividend. Clover Health Investments pays out -- of its earnings as a dividend.

Progyny quarterly revenues are $324M, which are smaller than Clover Health Investments quarterly revenues of $462.3M. Progyny's net income of $15.1M is higher than Clover Health Investments's net income of -$1.3M. Notably, Progyny's price-to-earnings ratio is 39.12x while Clover Health Investments's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Progyny is 1.73x versus 1.18x for Clover Health Investments. Usually stocks with elevated PS ratios are considered overvalued.

NeueHealth has a net margin of 4.65% compared to Progyny's net margin of -5.44%. Progyny's return on equity of 11.16% beat NeueHealth's return on equity of -3241.93%.

Progyny has a consensus price target of $26.25, signalling upside risk potential of 17.71%. On the other hand NeueHealth has an analysts' consensus of $7.00 which suggests that it could grow by 1.6%. Given that Progyny has higher upside potential than NeueHealth, analysts believe Progyny is more attractive than NeueHealth.

Progyny has a beta of 1.372, which suggesting that the stock is 37.195% more volatile than S&P 500. In comparison NeueHealth has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Progyny has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NeueHealth offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Progyny pays -- of its earnings as a dividend. NeueHealth pays out -- of its earnings as a dividend.

Progyny quarterly revenues are $324M, which are larger than NeueHealth quarterly revenues of $215.8M. Progyny's net income of $15.1M is higher than NeueHealth's net income of -$11.7M. Notably, Progyny's price-to-earnings ratio is 39.12x while NeueHealth's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Progyny is 1.73x versus 0.06x for NeueHealth. Usually stocks with elevated PS ratios are considered overvalued.

Oscar Health has a net margin of 4.65% compared to Progyny's net margin of 9.04%. Progyny's return on equity of 11.16% beat Oscar Health's return on equity of 10.83%.

Progyny has a consensus price target of $26.25, signalling upside risk potential of 17.71%. On the other hand Oscar Health has an analysts' consensus of $19.43 which suggests that it could grow by 10.91%. Given that Progyny has higher upside potential than Oscar Health, analysts believe Progyny is more attractive than Oscar Health.

Progyny has a beta of 1.372, which suggesting that the stock is 37.195% more volatile than S&P 500. In comparison Oscar Health has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Progyny has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Oscar Health offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Progyny pays -- of its earnings as a dividend. Oscar Health pays out -- of its earnings as a dividend.

Progyny quarterly revenues are $324M, which are smaller than Oscar Health quarterly revenues of $3B. Progyny's net income of $15.1M is lower than Oscar Health's net income of $275.3M. Notably, Progyny's price-to-earnings ratio is 39.12x while Oscar Health's PE ratio is 62.57x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Progyny is 1.73x versus 0.48x for Oscar Health. Usually stocks with elevated PS ratios are considered overvalued.